Introduction
Chronic heart failure (CHF) is a common medical condition affecting 2.2% of the population in Sweden (1) . Uncommon in persons aged younger than 50 years, CHF becomes more prevalent with increasing age and affects 6-10% of the population aged 65 years and older (2) . CHF impairs patients' quality of life, physical health and functioning, as well as cognitive health (3) (4) (5) . Besides hypertension, ischemic heart disease and atrial fibrillation, a frequent comorbidity in CHF is anemia (6) . Until recently the importance of iron deficiency as a stand-alone comorbidity in CHF, independent of anemia status, has been underestimated (7) . Iron deficiency seems to (i) be more common than anemia in CHF and affect up to 50% of patients, (ii) relate to disease severity of CHF, and (iii) be a strong and independent predictor of mortality with a greater predictive power than anemia (8, 9) . Mounting evidence and understanding of the role of iron deficiency in CHF has led to the acknowledgment of iron deficiency as a comorbidity in CHF by the European Society of Cardiology (ESC) in 2012 (10) .
Iron deficiency is amenable to medical treatment. Iron repletion with the intravenous (IV) iron preparation ferric carboxymaltose (FCM) * has shown promising results in the treatment of iron-deficient CHF patients in the FAIR-HF study (11) . The FAIR-HF was a multinational, placebo-controlled, double-blind, randomized phase III trial with 459 CHF patients with New
York Heart Association (NYHA) functional class II or III, a left ventricular ejection fraction of 40% or less (for patients in NYHA class II) or 45% or less (for NYHA class III), iron deficiency (defined as ferritin level <100 μg/L or 100-299 μg/L, if the transferrin saturation was <20%), and a hemoglobin level of 9.5-13.5 g/dL. Patients were randomly assigned to receive either ferric carboxymaltose (hereinafter referred to as the FCM group) or saline * FCM is marketed as Ferinject in Sweden by Vifor Pharma Nordiska AB, Stockholm, Sweden.
(hereinafter referred to as the placebo group) in a 2:1 ratio (12) . In the FCM group significant improvements were recorded in NYHA functional class, self-reported Patient Global Assessment, distance on the 6-Minute Walk Test, and health-related quality of life (HRQoL) compared with placebo after 24 weeks follow-up. The results were similar in patients with and without anemia (defined as hemoglobin level ≤12 g/dL at baseline). The rates of death as well as serious and non-serious adverse events were similar in the two study groups (11).
The Swedish healthcare system is decentralized with the provision of healthcare being mainly in the hands of 21 county councils and regions. Primary healthcare centers (PHCC) are the initial contact point with the healthcare system in non-acute cases (13) . Patients with symptoms of CHF are typically referred to hospital-based or PHCC-based heart failure (HF)
clinics for diagnosing and treatment initiation. Regular follow-up visits occur at HF clinics and partly also at ordinary PHCCs (14, 15) . Reimbursement of new drugs through inclusion in the national drug benefit scheme is decided by the Dental and Pharmaceutical Benefits Agency (TLV). The reimbursement decision is principally based on the cost-effectiveness of a new drug compared to the current standard treatment (13) . The TLV approved FCM for the treatment of iron deficiency in 2008 (16). However, neither FCM nor any other iron preparations are used to treat iron deficiency in CHF in clinical practice in Sweden today, as iron deficiency (as opposed to anemia) is not commonly tested for in CHF patients leaving the condition undetected and untreated.
The cost-effectiveness of FCM in iron-deficient CHF compared with placebo has previously been assessed in the context of the National Health Service in the UK (17) . Differences in healthcare systems and the exclusion of relevant treatment-related medical resources limit the external validity of these results. The aim of this study is to address these shortcomings and to examine the cost-effectiveness of FCM treatment compared with placebo in iron-deficient CHF patients from a Swedish healthcare perspective.
Methods
The cost-effectiveness analysis is built around the setup of the FAIR-HF trial but includes several adjustments to reflect current clinical practice in Sweden. The appropriate comparator for FCM treatment of iron deficiency in CHF is no treatment (represented by the placebo group), as under current clinical practice iron deficiency in CHF remains most often undetected and thus untreated. The time horizon in the analysis is 24 weeks corresponding to the follow-up period in the FAIR-HF trial. Even though it seems that the effects observed in this trial persist at least throughout the whole first year after treatment initiation (18), we have no data at hand which would justify an extrapolation of the time horizon.
The analysis estimates the health outcomes and the associated costs in each study group.
Health outcomes are measured as HRQoL and expressed in quality-adjusted life years (QALYs). Costs are obtained by combining resource use and unit cost data. Given the short time horizon, health outcomes and costs are not discounted. The result of the analysis is an incremental cost-effectiveness ratio (ICER), expressed in cost per QALY, which interrelates the difference in costs of treatment with FCM and placebo with the difference in HRQoL.
Health outcomes
The intention-to-treat population in the FAIR-HF trial was composed of 453 patients from ten
European countries and six patients from Argentina (11) . No patients were recruited in Sweden, but the clinical study results should be reasonably valid for the Swedish population given the predominantly European study population. 
Resource use
Our analysis takes the Swedish healthcare perspective and includes four resource categories which are directly affected by the treatment; diagnostic tests, FCM, administration of FCM, CHF-related hospitalization. Costs that fall outside the remit of the healthcare payer could not be included. Table 2 details all resource parameters used in the analysis.
In clinical practice FCM must only be administered, if the diagnosis of iron deficiency is based on laboratory tests (we include hemoglobin level, ferritin level and transferrin saturation). In the FCM group the resources for diagnosing all patients intended for treatment (and not only those with a positive diagnosis) are included, assuming a prevalence of iron deficiency of 50% in CHF (9) . The base case scenario does not include a separate healthcare visit for diagnostics, as this is probably physician-initiated in conjunction with a regular healthcare visit. However, we include a follow-up visit for diagnostic testing. In the placebo group no such resources are consumed, as these tests are not yet routinely performed in CHF patients in Sweden.
Dosing of FCM (and with that the number of administrations) is based on the approved simplified dosage regimen rather than the old regimen used in the FAIR-HF trial. Correct dosing is determined by the body weight and hemoglobin level resulting in four possible dosing combinations (we assume no patients with hemoglobin level ≥14 g/dL) (21) . In the base case scenario we assume a hypothetical patient population that is spread equally across all combinations. If administered as an IV infusion, the maximum single dose of FCM is 1,000 mg of iron per day and should not exceed 20 mg/kg body weight. As a result, 75% of the patients will require two healthcare visits to administer the cumulative iron dose and 25%
only one visit (we assume no patients with <50 kg body weight). The cumulative iron dose is supposed to suffice for 24 weeks.
As described before, the management of CHF patients is shared between healthcare providers in Sweden. Outpatient hospital care and primary care manage each around half of all CHF patients (14, 15) . Younger and more severe cases (as defined by NYHA class) are predominantly managed in outpatient hospital care (14, 15, 22) . In line with the patient recruitment in the FAIR-HF trial, it is expected that FCM will be mainly used in these patients. In the base case scenario we assume that 80% of the patients are treated in outpatient hospital care and 20% in primary care.
In the FAIR-HF trial there was a borderline significant trend towards a lower rate of hospitalization for any cardiovascular cause in the FCM group compared with the placebo group (hazard ratio 0.53; 95% confidence interval (CI) 0.25-1.09; p=0.08) (11) . Table 1 ); (ii) the Swedish prevalence estimate which includes patients with both CHF as primary and secondary diagnosis; (iii) the Swedish value referring solely to CHF and not any cardiovascular cause.
As hospital length of stay (LOS) in CHF patients varies greatly between countries (24), we do not apply the LOS recorded in the FAIR-HF trial to the number of hospitalizations per patient. Instead we use the average LOS of CHF patients in Sweden from the S-HFR (19) .
Unit costs
Swedish cost data on inpatient and outpatient care services at hospitals and in primary care
were sourced from the Board of the Southern Health Care Region, which utilizes a Diagnosis Related Groups system (25). Unit prices for FCM used in primary care were taken from the Swedish Medicines Information Engine (26) . Unit prices for FCM used in outpatient hospital care were provided by Vifor Pharma Nordiska, Stockholm, Sweden. All costs are reported in Swedish kronor (SEK) and euros (€) in 2014 prices; see Table 2 . An exchange rate of SEK 9.2 for €1 was applied.
Sensitivity analysis
Deterministic and probabilistic sensitivity analyses were conducted to examine the robustness of the resource parameters and the underlying assumptions in the base case. In the deterministic sensitivity analyses we simulated various scenarios to test the impact of a separate healthcare visit for diagnostic tests, the treatment setting (outpatient hospital care vs.
primary care) in which FCM is administered, dosing and cost of FCM, different definitions of the number of hospitalizations per patient, hospital LOS, computation of and the difference in QALY. In the probabilistic sensitivity analysis (second-order Monte Carlo simulation) we assumed a normal distribution of all parameters included; see Table 2 . 1,000 sets of randomly drawn input parameters were used. The analysis was performed in Microsoft ® Excel 2013
(Microsoft Corporation, Redmond, WA, USA).
Results
In the base case scenario, total costs per patient in the FCM group amounted to SEK 8,602
(€935) and to SEK 5,812 (€632) in the placebo group over the 24 weeks study period, corresponding to a cost difference of SEK 2,789 (€303 see Table 3 .
Our result is distinctly below the informal average reference value of SEK 500,000 (€54,300)
per QALY used by the TLV to determine cost-effectiveness. This indicates a favorable cost- 
Sensitivity analysis
In the deterministic sensitivity analysis the results ranged from an ICER of SEK 32,469 (€3,529) per QALY to SEK 164,081 (€17,835) per QALY; see Table 3 . The parameters with the greatest impact on the result were the QALY difference and its computation, the number of hospitalizations per patient, and the hospital LOS. The parameters with a modest impact were diagnostic tests, the healthcare setting in which FCM is administered, the dosing of FCM, and the unit cost of FCM.
The probabilistic sensitivity analysis led to an average difference in total costs of SEK 2,777 Figure 1 and Figure 2 , respectively. In short, the sensitivity analyses confirm the results to be robust.
Discussion
The economic burden of CHF is high and has been estimated to equal about 2% of the total healthcare budget in Sweden (14) . CHF patients are frequently hospitalized and CHF is the most common cause of hospitalization in patients aged over 65 years (19) . Hospitalization is by far the greatest cost component of total healthcare expenditure for CHF, accounting for 47-69% of total expenditures, whereas medications stand for some 18% and the remainder for nursing homes, primary and ambulatory care visits (14, 27) . Apart from the economic burden, CHF is a major cause of reduced HRQoL (4).
Only recently it has been discovered and acknowledged that iron deficiency (independent of anemia status) is a common and treatable comorbidity in CHF ( 
Limitations
Several limitations in our analysis originated from the design of the FAIR-HF trial. The most important ones were the short 24 weeks follow-up period, the usage of the old dosage regimen for the administration of FCM, and the underpowered study design to detect significant differences in hospitalizations. The CONFIRM-HF study addressed many of these issues.
The CONFIRM-HF was a multi-center, double-blind, placebo-controlled phase III trial with 304 iron-deficient CHF patients, who were treated with FCM according to the current dosage regimen over a 1-year period (18) . It is important to note that the CONFIRM-HF study used the same definition of iron deficiency as the FAIR-HF study and our findings should be interpreted against the backdrop of this definition of the eligible patient population.
Bearing strong resemblance to the FAIR-HF study, the CONFIRM-HF study recorded significant improvements in distance on the 6-Minute Walk Test, change in NYHA functional class, self-reported Patient Global Assessment, and HRQoL as well as similar number of deaths and adverse events rates in the FCM group compared to placebo (18) . These measures are partly captured by the number of QALYs, which we identified as a key driver of our result. This strengthens the evidence on the positive impact of FCM treatment on health outcomes and suggests a stable effect throughout the first year of treatment.
Since hospitalization constitutes the most important cost component in CHF patients, it is not surprising that the sensitivity analysis identified it as the other key driver of our result. In the FAIR-HF trial there was a clear trend towards a lower number of hospitalizations in patients receiving FCM compared with placebo, yet the difference was only borderline significant (11) , probably because the trial was not powered to detect such differences (12) . The CONFIRM-HF study observed an even stronger decrease in hospitalizations in the FCM group compared with placebo during the first year of treatment (18) . In our deterministic sensitivity analysis three scenarios utilize this newer data on hospitalization. They indicate more favorable outcomes than the base case result.
In the estimation of costs for FCM and its administration, we applied the current dosage regimen to a hypothetical patient population, which was supposed to better reflect the eligible population in clinical practice. In the base case scenario the average amount of iron administered was 1,500 mg, and the average number of administrations was 1.75. The outcomes of the CONFIRM-HF study supported our approach, as throughout the first year of treatment the average amount of iron administered was 1,500 mg, and over 75% of the patients required a maximum of two administrations of FCM to correct and maintain the iron parameters (18).
We used conservative assumptions in the estimation of costs for diagnostic tests. In the placebo group we assumed no diagnostic tests, even though the hemoglobin level is routinely assessed in CHF patients in Sweden. In case of abnormal findings further laboratory tests may be performed, which possibly examine the ferritin level and transferrin saturation. We did not include the cost for a separate healthcare visit to perform the initial diagnostic tests, as this will probably be initiated by a physician in conjunction with one of the several outpatient care
visits that a CHF patient typically makes each year due to the treatment of numerous comorbidities (14, 22) . For the same reason, the costs for a follow-up visit to check the iron parameters, which we included, might be overestimated.
The inability to take on a societal perspective in our analysis and include resources outside the remit of the healthcare payer, such as productivity loss and informal care, should not invalidate our results. For the United States it has been estimated that indirect costs constitute 
Conclusion
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